Pharmaceutical Drug Delivery Market Segments, Opportunity, Growth and Forecast by End-use Industry 2023 to 2033

 The global Pharmaceutical Drug Delivery Market is projected to have a high-paced CAGR of 6.4% during the forecast period. The current valuation of the pharmaceutical drug delivery market is US$ 1.9 trillion in 2023. The value of the pharmaceutical drug delivery market is anticipated to reach a high of US$ 3.5 trillion, by the year 2033.

.Request Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-14307

A vast increase in the frequency of deaths among the elderly and cancer patients is fueling demand for pharmaceutical medication delivery systems. These systems improve the effectiveness and toxicity of anticancer drugs. The market expansion can be attributed to fast-increasing research and development investments by pharmaceutical development companies. This is primarily done to concentrate on the discovery of effective therapies for chronic and noncommunicable diseases such as cancer, diabetes, and hypertension. Taris, an research & development-based biomedical business, for example, has a controlled-release drug delivery system in its pipeline product TAR-200 (Gemcitabine), which is indicated for the treatment of bladder cancer.



In addition, Johnson & Johnson finalized the acquisition of Taris Biomedical in 2019. One of the primary motivations for the purchase is said to be its principal investigational medicine, TAR-200. The development of new goods with improved safety and usability is expected to attract the vast pharmaceutical industry. Furthermore, improved dosage characteristics complement pharmacological treatment outcomes and expand the possibility for illness management in home care settings.

For instance, Ypsomed announced YpsoMate in November 2021, claiming it to be the world's first auto-injector for prefilled syringes with an integrated connection. It is suitable for self-administration. Moreover, industry participants are increasingly collaborating with pharmaceutical firms to develop and commercialize goods. KINDEVA DRUG DELIVERY, for instance, joined with Cambridge Healthcare Innovations Limited (CHI) in April 2021 to develop and market CHI's eolus dry-powder inhaler (DPI) platform technology. Topical pharmaceutical drug delivery entails drug transfer from a product on the skin to a local target location, followed by clearance to the rest of the body and deeper tissues via diffusion, metabolism, and dermal circulation.

According to statistics published in the World Health Organization's Global Health Expenditure Database in 2016, the average per capita public spending on health in middle-income countries has more than doubled since 2000, as these nations progress in their transition to domestic funding. Global health spending in 2016 was US$ 7.50 trillion, which equates to 10.0% of the global GDP. The increased execution of strategic initiatives and the creation of unique goods are the primary drivers driving the segment's growth. In March 2021, for example, scientists at Stanford University and the University of North Carolina at Chapel Hill (UNC) developed a 3D-printed vaccination patch that they claim gives better protection than a standard vaccine injection. The creation of such unique goods is fueling the use of medication delivery products, which is boosting the market growth. ​

However, various regulatory approval techniques are used for highly sophisticated items. The severe rules imposed by regulatory organizations to evaluate product performance and safety are projected to hinder the introduction of technologically sophisticated and novel items throughout the forecast period.

Get Full Access @ https://www.futuremarketinsights.com/reports/pharmaceutical-drug-delivery-market

Key Takeaways:

  • The United States is expected to dominate the global pharmaceutical medication delivery market during the forecast period. Obesity rates in the United States are rising owing to rapid changes in lifestyle, resulting in a slew of chronic ailments such as diabetes and heart disease. Nanotechnology advances have significantly improved drug design, enabling focused, safe, and effective medicinal formulations including nanoparticles (NP).
  • Throughout the estimated period, China is expected to lead the Asia Pacific pharmaceutical drug delivery market. The growing prevalence of chronic diseases in China has increased the use of medication delivery systems, particularly disposable needles. The International Diabetes Federation's Diabetes Atlas 2021 predicts that the age-adjusted comparative prevalence of diabetes in China in 2021 is expected to be 10.6%, 11.8% in 2030, and 12.5% in 2045.
  • Owing to the simplicity of consumption, the ‘oral drug delivery’ route of administration type is expected to hold the greatest revenue, through the forecast period.
  • As the majority of income earned by biotech and pharmaceutical businesses offers resources to the healthcare industry, the ‘infectious diseases application type is the most creative segment for key companies, accounting for a sizable portion.

Competitive Landscape:

Given the presence of both foreign and local rivals, the global pharmaceutical drug delivery market share is split. Several firms have a substantial market share in their respective sectors. Organic developments, such as product approvals and the global rise in chronic diseases, are typically valued by large corporations. As a consequence of these factors, the global pharmaceutical drug delivery market is expected to increase rapidly.

Key Players:

  • Novartis International AG
  • Hoffmann-La Roche AG
  • Pfizer Inc.
  • Becton Dickinson & Company
  • GlaxoSmithKline PLC
  • Merck & Co Inc
  • Sanofi S.A.
  • Bayer Medicine Products AG
  • 3M

Recent Developments:

  • In December 2020, Pfizer, Inc. received United States FDA clearance for BRAFTOVI (encorafenib) with cetuximab to treat patients with brafv600e-mutant metastatic colorectal cancer who have previously undergone therapy (CRC).
  • In July 2021, Darzalex, a subcutaneous solution developed by Johnson & Johnson, was approved by the United States Food and Drug Administration.

Key Segments Profiled

By Route of Administration:

  • Oral Drug Delivery
  • Injectable Drug Delivery
  • Topical Drug Delivery
  • Ocular Drug Delivery
  • Pulmonary Drug Delivery
  • Nasal Drug Delivery
  • Transmucosal Drug Delivery
  • Implantable Drug Delivery

By Application:

  • Infectious Diseases
  • Cancer
  • Cardiovascular Diseases
  • Diabetes
  • Respiratory Diseases
  • Central Nervous System Disorders
  • Autoimmune Diseases
  • Others

By Facility of Use:

  • Hospitals
  • Ambulatory Surgery Centers/Clinics
  • Home Care Settings
  • Diagnostic Centers
  • Others

Comments

Post a Comment

Popular posts from this blog

Pet Diabetes Care Devices Market Report | Size, Growth, Demand, Scope and Forecast to 2032

  The global  Pet Diabetes Care Devices Market  is expected to grow at a  6.5%  CAGR, reaching  US$ 4 billion  by 2032, up from  US$ 2 billion  in 2021. “The number of pets with diabetes, the number of adopted pets, and the number of overweight pets are all driving the market forward.” Get Full Access @ https://www.futuremarketinsights.com/reports/pet-diabetes-care-devices-market The domestication of animals is leading to a lack of insulin production in them. The limited flow of glucose to the cell can be termed diabetes. This chronic disease is a major concern for pet owners and needs to be taken care of. This concern leads to the expansion of the pet diabetes care devices market. Devices like the alphatrak blood glucose meter are in use as they help the pet owners monitor the pet’s health. The increased number of people adopting pets and then domesticating them around in their households, treating and caring for them as f...
Read more

Human Immunodeficiency Virus Type 1 (HIV 1) Market Opportunity, Competitive Analysis, Future Prospects to 2033

Image
  The global Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to exceed a remarkable valuation of US$ 34.83 Billion in 2023, with a compound annual rate of growth (CAGR) of 6% estimated from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes the industry's growth to the soaring incidence rate of HIV-1 infection, which, unlike the deaths caused from this viral illness, has not updated substantially over time. Get Full Access @ https://www.futuremarketinsights.com/reports/human-immunodeficiency-virus-type-1-hiv1-market It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate. The World Health Organization (WHO) estimates that 33.0 million...
Read more

Clostridium Diagnostics Market in US is anticipated to secure a market value worth US$ 2.7 Billion by 2032 | FMI

Image
  The global Clostridium Diagnostics Market is expected to grow at a CAGR of 12.2% during the forecast period, from US$ 2.5 billion in 2022 to US$ 7.8 billion by 2032. The market grew at a CAGR of 13.6% between 2015 and 2021. The rising prevalence of clostridium-related diseases, as well as increased campaigns to educate people about the condition, are driving the market growth. To learn more about this report @ https://www.futuremarketinsights.com/reports/clostridium-diagnostics-market here has been an increased focus of players in the market to offer vaccines, which can augment the market size in the forecast period. For instance, in March 2022, Japan launched a new center, with a budget of US$ 1.6 Billion, to support vaccine and drug projects as a part of a larger scheme to tackle infectious diseases. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects. Awareness camp...
Read more